UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000020601 |
|---|---|
| Receipt number | R000023778 |
| Scientific Title | A phase II study of Nivolumab for relapsed/refractory adult T-cell leukemia/lymphoma (ATL) |
| Date of disclosure of the study information | 2016/01/17 |
| Last modified on | 2022/11/12 16:06:28 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase II study of Nivolumab for relapsed/refractory adult T-cell leukemia/lymphoma (ATL)
Acronym
A phase II study of Nivolumab for relapsed/refractory ATL
Scientific Title
A phase II study of Nivolumab for relapsed/refractory adult T-cell leukemia/lymphoma (ATL)
Scientific Title:Acronym
A phase II study of Nivolumab for relapsed/refractory ATL
Region
| Japan |
Condition
Condition
Adult T-cell Leukemia/Lymphoma (ATL)
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To elucidate the efficacy and safety of Nivolumab for patients with relapsed or refractory aggressive ATL (acute, lymphoma, and chronic type with unfavorable prognostic factors) who had been treated by or intolerance/contraindication for mogamulizumab.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
response rate (best overall response)
Key secondary outcomes
safety, response rate for relapsed ATL (best overall response), response rate for refractory ATL (best overall response), response rate according to disease sites (best overall response), progression free survival, overall survival, time to next treatment
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Nivolumab will be administered at a dose of 3 mg per kilogram of body weight by intravenous infusion every 2 weeks until patients' condition meets discontinuance criteria.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Hematocytologically or pathohistologically proved peripheral lymphoid malignancy expressing T cell phenotype with positivity of anti-HTLV-1 antibody.
2) Relapsed or refractory ATL patients after one or more prior lines of chemotherapy under the diagnosis of aggressive ATL (acute type, lymphoma type, or chronic type with unfavorable factor).
3) Aged 20 or older
4) Performance status (ECOG) 0-2
5) Having at least one of measurable lesion, or evaluable lesion in either of peripheral blood or skin.
6) Fulfilling all of following for prior treatment
1. At least one regimen of cytotoxic chemotherapy and mogamulizumab, or at least one regimen of cytotoxic chemotherapy in case of intolerance/contraindication for mogamulizumab.
2. No history of treatment of immune checkpoint inhibitors (anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody).
3. More than 4 weeks of interval from the last chemotherapy to the scheduled first day of protocol treatment for ATL (excluding oral or external adrenocorticoids).
4. More than 4 weeks of interval from the last treatment by antibodies for ATL to the scheduled first day of protocol treatment
5. More than 4 weeks of interval from the last radiation for ATL to the scheduled first day of protocol treatment.
6. No history of treatment for other malignancies by chemotherapy and/or radiation.
7. No history of organ transplantation and/or allogenic hematopoietic stem cell transplantation.
8. More than 4 weeks of interval from the last administration of investigational drugs.
7) Adequate organ functions
8) Expected more than 3 months of survival
9) Written informed consent from the patient.
10) Women who can possibly become pregnant must agree to use birth control methods, and nursing women must agree to refrain it for 320 days from the last dose of the study drug.
11) Male must agree to the use of contraceptions for 320 days from the last dose of the study drug.
Key exclusion criteria
1) Synchronous or metachronous malignancy except carcinoma in situ or cancer confined to the mucosa and curatively treated by local resection.
2) Active infection requiring systemic treatment
3) Pregnant or nursing women
4) Psychological disturbance
5) Administration of systemic adrenocorticoids more than 10mg/day of predonisolone or equivalents except for the treatment of ATL, medical examination, or prophylactic use for allergic reaction, and/or immunosuppressants.
6) Diabetes mellitus poorly controlled and regularly treated by insulin.
7) Poorly controlled hypertension
8) Unstable angina and/or myocardial infarction within 6 months.
9) HBs-Ag positive or HBc-Ab positive with HBV-DNA positive.
10) HCV-Ab positive
11) HIV-Ab positive
12) Complication or history of interstitial pneumonia or pulmonary fibrosis diagnosed by image and/or symptoms
13) Complication or history of autoimmune diseases.
14) Suspicious findings of central nervous invasion.
15) Other inadequate conditions determined by investigators.
Target sample size
22
Research contact person
Name of lead principal investigator
| 1st name | Ishitsuka |
| Middle name | |
| Last name | Kenji |
Organization
Kagoshima University Hospital
Division name
Department of Hematology and Immunology
Zip code
890-8544
Address
8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
TEL
099-275-5934
kenji-i@m.kufm.kagoshima-u.ac.jp
Public contact
Name of contact person
| 1st name | Toshitaka |
| Middle name | |
| Last name | Futagawa |
Organization
Kagoshima University Hospital
Division name
Clinical Research Management Center
Zip code
890-8520
Address
8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
TEL
099-275-5553
Homepage URL
nivo-cc@m.kufm.kagoshima-u.ac.jp
Sponsor or person
Institute
The study group for investigator-oriented clinical trial for the development of treatment of ATL.
Institute
Department
Personal name
Funding Source
Organization
ONO PHARMACEUTICAL CO., LTD
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kagoshima University Hospital, Clinical Trial Review Board
Address
8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
Tel
099-275-5553
chiken@m3.kufm.kagoshima-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
鹿児島大学病院（鹿児島県）
国立病院機構熊本医療センター（熊本県）
名古屋市立大学病院（愛知県）
今村総合病院（鹿児島県）
福岡大学病院（福岡県）
熊本大学病院（熊本市）
九州大学病院（福岡市）
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 01 | Month | 17 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2015 | Year | 11 | Month | 30 | Day |
Date of IRB
| 2015 | Year | 12 | Month | 16 | Day |
Anticipated trial start date
| 2016 | Year | 01 | Month | 17 | Day |
Last follow-up date
| 2027 | Year | 09 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 01 | Month | 17 | Day |
Last modified on
| 2022 | Year | 11 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023778
